

Report to:	Public Board of Directors	Agenda item:	19
Date of Meeting:	6 March 2024		
Title of Report:	Alert, Advise and Assure Report – FPC Committee		
Status:	For information		
Author:	Antony Durbacz, Non-Executive Director and FPC Chair		

Key Discussion Points and Matters to be escalated from the meeting held on 27/2/24

ALERT: Alert to matters that require the board’s attention or action, e.g. non-compliance, safety or a threat to the Trust’s strategy

- The Committee reviewed the draft business plan for 23/24 which is presented at the private board meeting. It noted that there had been delay in receiving the appropriate planning guidance which had hampered its compilation. In addition, the operational and financial challenges included were significant and would require a considerable improvement in performance to be achieved

ADVISE: Advise of areas of ongoing monitoring or development or where there is negative assurance

- Industrial action continues to impact operational and financial performance
- The forecast outturn of a deficit of £5.8m remains under pressure with the achievement of targeted cost savings an essential part.
- Operational performance trajectories for 62 day cancer and 4hour emergency care continue to be challenging with diagnostic capacity being an issue for cancer pathways
- Underlying RTT performance is encouraging but with particular issues noted in “weight reduction” pathways.
- ERF margin performance is improving but needs to be higher to hit the forecast projections.
- The improvement delivery plan for the year and the “hopper” for next year continue to evolve.
- Trust and external capital are underspent, work is underway to ensure the funds are spent before the year end
- Cashflow in the early part of 24/25 is under pressure and will probably need central funding to be drawn

ASSURE: Inform the board where positive assurance has been achieved

- Improving performance in diagnostics (DM01) where the forecast trajectories are being met.
- Sulis performance continues to improve

RISK: Advise the board which risks were discussed and if any new risks were identified.

N/A

CELEBRATING OUTSTANDING: Share any practice, innovation or action that the committee considers to be outstanding

N/A

APPROVALS: Decisions and Approvals made by the Committee

- The committee recommends to the board the approval requested in the Sulis options appraisal.

The Board is asked to NOTE the content of the report.